Julie Brown Purchases 8 Shares of GSK (LON:GSK) Stock

Key Points

• Insider Julie Brown purchased 8 shares of GSK stock on September 9th for an average cost of GBX 1,486 per share, totaling £118.88.
• GSK shares traded down 0.3% to GBX 1,485.98, with a market cap of £59.85 billion and a PE ratio of 1,796.83.
• Analysts have mixed ratings on GSK, with one "Buy," two "Hold," and one "Sell" recommendation, and a consensus target price of GBX 1,637.50.

GSK plc (LON:GSK - Get Free Report) insider Julie Brown bought 8 shares of the company's stock in a transaction that occurred on Tuesday, September 9th. The shares were acquired at an average cost of GBX 1,486 per share, with a total value of £118.88.

Julie Brown also recently made the following trade(s):

• On Monday, August 11th, Julie Brown bought 9 shares of GSK stock. The shares were acquired at an average cost of GBX 1,408 per share, with a total value of £126.72.

GSK Stock Down 1.6%

GSK stock traded down GBX 24.50 during midday trading on Monday, hitting GBX 1,479. 13,732,532 shares of the company were exchanged, compared to its average volume of 12,314,056. The company's fifty day moving average price is GBX 1,428.95 and its 200-day moving average price is GBX 1,432.29. The company has a market cap of £59.57 billion, a PE ratio of 1,788.39, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73. GSK plc has a fifty-two week low of GBX 1,242.50 and a fifty-two week high of GBX 1,649.25.

GSK (LON:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported GBX 75.30 EPS for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, research analysts predict that GSK plc will post 175.980975 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Shore Capital reissued a "buy" rating and set a GBX 2,100 price target on shares of GSK in a research report on Wednesday, August 27th. Berenberg Bank reissued a "hold" rating and set a GBX 1,600 price target on shares of GSK in a research report on Friday, July 18th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and set a GBX 1,450 price target on shares of GSK in a research report on Thursday, July 31st. Finally, JPMorgan Chase & Co. dropped their price objective on GSK from GBX 1,460 to GBX 1,400 and set an "underweight" rating on the stock in a report on Monday, August 4th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of GBX 1,637.50.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.